BEDMINSTER, N.J., and DUBLIN, Ireland, June 21, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the results from a Phase 1 clinical trial that compared bioavailability of components from a fixed-dose combination of its flagship product, Vascepa® (icosapent ethyl), plus rosuvastatin, to concomitant administration of the two agents independently, and to rosuvastatin alone.
"The encouraging results of this pharmacokinetic study represent a crucial step in the plan to solidify a fixed-dose formulation of Vascepa capsules with statins," stated Joseph Zakrzewski, Chairman and Chief Executive Officer of Amarin.
In the multiple-dose study of 48 healthy volunteers, AMR-102 (the fixed-dose combination of icosapent ethyl and rosuvastatin, a leading statin) was assessed versus simultaneous administration of the individual agents, as well as versus rosuvastatin monotherapy, on pharmacokinetic measurements in order to show feasibility of the fixed-dose combination. The results proved promising, as there was no inhibition of either the rosuvastatin bioavailability, or of the bioavailability of the active metabolite EPA from Vascepa, observed with the fixed-dose combination product compared to the other arms of the trial.The AMR-102 test formulation was well tolerated. No serious adverse events were reported in the Phase 1 trial, nor was there an increase in reported side effects with either the fixed-dose combination, or the arm given co-administration of the two agents, versus those who received rosuvastatin alone. In the ANCHOR trial, Vascepa showed robust reductions in TGs and a broad range of other lipid parameters on top of optimized statin therapy, including atorvastatin, simvastatin, and rosuvastatin. Based on these encouraging efficacy results from ANCHOR, technical considerations, and market research, rosuvastatin was selected for this initial proof-of-principle pharmacokinetic study. The results of this Phase 1 study with rosuvastatin and Vascepa also bode well for the feasibility of applying this fixed-dose combination approach to a broader range of statins.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts